| Dr Basel Baghal, DO | |
|
1 Maywood Ave, Maywood, NJ 07607-1001 | |
| (201) 464-4755 | |
| (201) 464-4758 |
| Full Name | Dr Basel Baghal |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 8 Years |
| Location | 1 Maywood Ave, Maywood, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1356703409 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 25MB10634800 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Hackensack University Medical Center | Hackensack, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Optum Medical Care Of New Jersey Pc | 3072650290 | 231 |
News Archive
RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using targeted biotherapeutics, announced updated data from its Phase 2 clinical trial of NeuVax at the American Society of Clinical Oncology (ASCO) annual meeting.
The Leuven-based VIB researchers have revealed a mechanism that explains why the anti-tumor activity of specific immune cells called macrophages is suppressed during tumor growth. They have also demonstrated that blocking the protein Nrp1 can restore this anti-tumor immune response.
Pharmacyclics LLC today highlighted results from a sub-analysis of the Phase III RESONATE™ (PCYC-1112) trial, which found that previously-treated patients with chronic lymphocytic leukemia (CLL) who adhered to the recommended 420 mg dose of IMBRUVICA® (ibrutinib) experienced improved progression-free survival (PFS; the primary endpoint) as assessed by an Independent Review Committee (IRC), compared to patients who took lower doses or missed doses, regardless of high-risk genetic factors.
People who live near livestock or in livestock farming communities may be at greater risk of acquiring, Methicillin-resistant Staphylococcus Aureus (MRSA), according to a new study led by an international team of researchers from the Johns Hopkins Bloomberg School of Public Health, the Dutch Institute for Public Health and the Environment (RIVM) and VU University Medical Center in Amsterdam.
Despite evidence that cervical cancer screening saves lives, about eight million women ages 21 to 65 years have not been screened for cervical cancer in the past five years, according to a new Vital Signs report from the Centers for Disease Control and Prevention. More than half of new cervical cancer cases occur among women who have never or rarely been screened.
› Verified 1 days ago
| Entity Name | Optum Medical Care Of New Jersey Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578665048 PECOS PAC ID: 3072650290 Enrollment ID: O20091021000129 |
News Archive
RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using targeted biotherapeutics, announced updated data from its Phase 2 clinical trial of NeuVax at the American Society of Clinical Oncology (ASCO) annual meeting.
The Leuven-based VIB researchers have revealed a mechanism that explains why the anti-tumor activity of specific immune cells called macrophages is suppressed during tumor growth. They have also demonstrated that blocking the protein Nrp1 can restore this anti-tumor immune response.
Pharmacyclics LLC today highlighted results from a sub-analysis of the Phase III RESONATE™ (PCYC-1112) trial, which found that previously-treated patients with chronic lymphocytic leukemia (CLL) who adhered to the recommended 420 mg dose of IMBRUVICA® (ibrutinib) experienced improved progression-free survival (PFS; the primary endpoint) as assessed by an Independent Review Committee (IRC), compared to patients who took lower doses or missed doses, regardless of high-risk genetic factors.
People who live near livestock or in livestock farming communities may be at greater risk of acquiring, Methicillin-resistant Staphylococcus Aureus (MRSA), according to a new study led by an international team of researchers from the Johns Hopkins Bloomberg School of Public Health, the Dutch Institute for Public Health and the Environment (RIVM) and VU University Medical Center in Amsterdam.
Despite evidence that cervical cancer screening saves lives, about eight million women ages 21 to 65 years have not been screened for cervical cancer in the past five years, according to a new Vital Signs report from the Centers for Disease Control and Prevention. More than half of new cervical cancer cases occur among women who have never or rarely been screened.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Basel Baghal, DO 1 Maywood Ave, Maywood, NJ 07607-1001 Ph: (201) 464-4755 | Dr Basel Baghal, DO 1 Maywood Ave, Maywood, NJ 07607-1001 Ph: (201) 464-4755 |
News Archive
RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using targeted biotherapeutics, announced updated data from its Phase 2 clinical trial of NeuVax at the American Society of Clinical Oncology (ASCO) annual meeting.
The Leuven-based VIB researchers have revealed a mechanism that explains why the anti-tumor activity of specific immune cells called macrophages is suppressed during tumor growth. They have also demonstrated that blocking the protein Nrp1 can restore this anti-tumor immune response.
Pharmacyclics LLC today highlighted results from a sub-analysis of the Phase III RESONATE™ (PCYC-1112) trial, which found that previously-treated patients with chronic lymphocytic leukemia (CLL) who adhered to the recommended 420 mg dose of IMBRUVICA® (ibrutinib) experienced improved progression-free survival (PFS; the primary endpoint) as assessed by an Independent Review Committee (IRC), compared to patients who took lower doses or missed doses, regardless of high-risk genetic factors.
People who live near livestock or in livestock farming communities may be at greater risk of acquiring, Methicillin-resistant Staphylococcus Aureus (MRSA), according to a new study led by an international team of researchers from the Johns Hopkins Bloomberg School of Public Health, the Dutch Institute for Public Health and the Environment (RIVM) and VU University Medical Center in Amsterdam.
Despite evidence that cervical cancer screening saves lives, about eight million women ages 21 to 65 years have not been screened for cervical cancer in the past five years, according to a new Vital Signs report from the Centers for Disease Control and Prevention. More than half of new cervical cancer cases occur among women who have never or rarely been screened.
› Verified 1 days ago
Kamran Ismail Hamirani, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 255 W Spring Valley Ave, Suite 201, Maywood, NJ 07607 Phone: 201-996-0055 Fax: 201-996-0584 | |
Niren Jasutkar, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1 Maywood Ave, Maywood, NJ 07607 Phone: 551-257-7005 | |
Dr. Han Ngoc Nguyen, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 255 W. Spring Valley Ave, Suite 100, Maywood, NJ 07601 Phone: 201-881-0107 | |
Dr. Eugene C French, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 255 W Spring Valley Ave, Suite 200, Maywood, NJ 07607 Phone: 201-343-2778 Fax: 201-343-1990 | |
Dr. Demetrios Nicholas Panagiotou, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 255 W Spring Valley Ave Ste 200, Maywood, NJ 07607 Phone: 201-882-6088 Fax: 201-882-6063 | |
Dr. Ari Geliebter, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 240 W Passaic St Ste 14, Maywood, NJ 07607 Phone: 201-903-0070 Fax: 201-322-0287 |